# Rampart Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rampart-bioscience

- Industry: Biotechnology
- Headquarters: US
- Website: www.rampartbio.com/
- Total disclosed funding: $101M
- Latest round: Seed (Oct 24, 2023)
- Investors on record: 4

## About

Founded in 2019 and based in California, US, Rampart Bioscience, Inc., operates as a biotech company that develops gene medicines and offers proprietary development and delivery platforms. In October 2023, Rampart Bioscience, Inc., raised USD 85 million in series A funding led by Forbion, with participation from other new investors, HealthCap and RA Capital Management. As of 2023, the company was founded by its Chief Innovation and Technical Officer, Jeffrey Bartlett, CEO, Louis Breton.

The company offers various gene therapy solutions that include gene delivery, protein sciences, and clinical translation solutions.

The company uses a non-viral DNA delivery system used for treating an inherited metabolic disorder and high-need applications in genetic disease.

The company plans to use the October 2023 funding to increase operations and its research and development activities.

## Funding rounds

- Seed, Oct 24, 2023, $40M — OrbiMed Advisors
- Series A, Sep 11, 2023, $61M — OrbiMed Advisors, HealthCap, Forbion, RA Capital Management

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Seed
- HealthCap — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A